Cargando...
Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease
BACKGROUND: TreXTAM(® )is a combination of the key regulatory cytokine transforming growth factor beta (TGFβ) and all trans retinoic acid (ATRA) microencapsulated for oral delivery to immune structures of the gut. It is in development as a novel treatment for inflammatory bowel disease (IBD). AIM: T...
Gardado en:
| Publicado en: | World J Gastrointest Pharmacol Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Baishideng Publishing Group Inc
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7667406/ https://ncbi.nlm.nih.gov/pubmed/33251033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4292/wjgpt.v11.i5.79 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|